Fatty Acid Ophthalmic Formulations for Gonococcal Eye Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prophylaxis and treatment options for Neisseria gonorrhoeae infections, particularly ophthalmia neonatorum, are inadequate due to rising antibiotic resistance, with existing treatments being either ineffective or causing adverse effects, and there is a need for alternative non-antibiotic solutions to prevent and treat eye infections in infants and adults.
Innovation Solution
The use of fatty acid compounds such as myristoleic acid, palmitoleic acid, and capric acid monoglyceride (monocaprin) in ophthalmic formulations as a prophylaxis or treatment for Neisseria gonorrhoeae infections, potentially combined with chelating agents to enhance efficacy and stability, formulated as eye drops, ointments, or hydrogels for ocular administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic-based prophylaxis (tetracycline or erythromycin) is used, then protection against N. gonorrhoeae infection is provided, but antibacterial resistance develops and treatment effectiveness decreases
Solution Approach 1:
The patent changes the chemical parameter of the prophylaxis agent from antibiotic compounds to fatty acid compounds (specifically caprylic acid, capric acid, lauric acid, and myristic acid). This parameter change allows the prophylaxis to remain effective against N. gonorrhoeae while avoiding the development of antibacterial resistance that occurs with antibiotic-based treatments.
Solution Approach 2:
The patent employs simple fatty acid compounds that can be easily synthesized and formulated as ophthalmic preparations. These compounds act locally in the eye to prevent infection without requiring long-term systemic antibiotic therapy, thereby reducing the selection pressure that leads to resistance development.
2Adaptability or versatility
If silver nitrate is used for prophylaxis, then historical treatment option is provided, but treatment-induced conjunctivitis and toxicity occur with high incidence
Solution Approach 1:
The patent replaces silver nitrate (an inorganic compound) with fatty acid compounds (organic compounds). This parameter change in chemical composition eliminates the toxic side effects and conjunctivitis associated with silver nitrate while maintaining prophylactic effectiveness against N. gonorrhoeae.
Solution Approach 2:
The patent converts the potential harm of using harsh chemical agents (like silver nitrate) into benefit by selecting fatty acid compounds that have inherent antimicrobial activity against N. gonorrhoeae but are gentle enough not to cause conjunctivitis or toxicity. The fatty acids naturally occur in breast milk and are biocompatible.
3Reliability
If current antibiotic treatments are used, then infection treatment is attempted, but multidrug-resistant cases require dual therapy and completely resistant cases exist
Solution Approach 1:
The patent extracts the core protective function from complex antibiotic regimens and implements it through simple fatty acid compounds applied topically to the eye. This extraction approach prevents infection before it establishes, eliminating the need for complex dual-antibiotic therapies required for multidrug-resistant cases.
Solution Approach 2:
The patent applies fatty acid compounds prophylactically to the newborn's eyes immediately after birth, before N. gonorrhoeae infection can establish. This preliminary action prevents the need for later complex treatments that would be required if resistance had already developed.
4Loss of information
If prenatal screening is implemented, then infection risk is identified, but up to 40% of pregnant women who should be evaluated are not tested
Solution Approach 1:
The patent makes prophylaxis universally applicable to all newborns regardless of maternal screening status. By applying fatty acid compounds to every newborn's eyes, the system eliminates the need for complex screening protocols and ensures no infant is left unprotected due to non-compliance with prenatal testing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These fatty acid compounds demonstrate bacteriostatic and bactericidal properties against Neisseria gonorrhoeae, are non-irritant to the eye, and retain antigonococcal activity for at least 9 months when stored at room temperature, offering a viable alternative to antibiotic-based treatments in the face of increasing resistance.
Implementation Method 1
These fatty acid compounds demonstrate bacteriostatic and bactericidal properties against Neisseria gonorrhoeae
Data Source
Figure 1~4
Figure 5~7
Figure 8~9
AI summary
Provided is the use of a fatty acid or fatty acid ester, or a pharmaceutically acceptable salt or solvate thereof, selected from capric acid C10:0 monoglyceride, undecanoic acid C11:0, lauric acid C12:0, tridecanoic acid C13:0, myristic acid C14:0, pentadecylic acid C15:0, myristoleic acid C14:1cΔ9, palmitoleic acid C16:1cΔ9, oleic acid C18:1cΔ9, elaidic acid C18:1tΔ9, erucic acid C22:1cΔ13, linoleic acid C18:2cΔ9,12, linolenic acid C18:3cΔ9,12,15, lauric acid C12:0 monoglyceride, myristic acid C14:0 monoglyceride, ricinoleic acid, lauric acid C12:0 sodium salt, and myristic acid C14:0 sodium salt, for the treatment or prophylaxis of an infection of the eye caused by Neisseria gonorrhoeae in a warm-blooded animal, particularly in a newborn human. Also provided is an ophthalmic formulation comprising the fatty acid or ester, for example an eye drop liquid, an ointment or a hydrogel.